Trial Profile
Trastuzumab in combination with S-1/CDDP in HER2-positive advanced gastric cancer: a phase II trial.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 20 Nov 2013 Planned End Date changed from 31 Dec 2014 to 30 Jun 2016 as reported by University Hospital Medical Information Network - Japan record.
- 17 Jun 2013 Planned end date added (31 Dec 2014) as reported by University Hospital Medical Information Network - Japan record.
- 27 Jul 2012 Additional lead trial centers identified as reported by University Hospital Medical Information Network - Japan.